Navigation Links
Chemo Patients Pose Potential Public Health Risk
Date:9/19/2013

NEWPORT, R.I., Sept. 19, 2013 /PRNewswire-iReach/ -- In its second edition of "Safe Management of Wastes from Health-Care Activities," released in August, the World Health Organization (WHO) singled out contact with residual amounts of chemotherapy drugs as a significant risk requiring collection, containment and proper disposal in order to avoid exposure "through contact with body fluids and secretions [urine, feces and vomit] of patients undergoing chemotherapy."

Genotoxic/cytotoxic compounds, most commonly found in chemotherapy drugs, work by either mutating or killing cells. Unlike poisons, which can be safe when exposure is limited to tiny amounts, genotoxins/cytotoxins act more like "chemical germs," where even minimal exposure can cause a devastating chain reaction. The risk from contact to an otherwise healthy person is especially heightened when there is a significant amount of cell development happening — for example, among children and women of childbearing age.

According to the WHO report, any wastes produced by these patients within 48 hours of drug administration, and in some cases for up to a week, should be considered genotoxic.

Despite the otherwise well-regulated and well-managed handling of dangerous medical waste, chemotherapy patients treated with any of more than two dozen different chemotherapy drugs who return home after outpatient treatment can inadvertently but easily expose others to genotoxic contamination through seemingly benign occurrences such as urine splashed on a bathroom floor, clean up after an episode of vomiting, or the handling of bed sheets or a bedpan for a patient unable to use a bathroom.

The WHO report address what many in the field of chemotherapy-based treatment have long acknowledged as a dangerous "blind spot."
The human body can only destroy a portion of these genotoxic drugs. The rest passes out of the patient in urine, feces, vomit, or even sweat. The waste will still have enough dangerous drug to kill developing cells and/or cause mutations in vulnerable members of our population, especially fetuses and babies.

The WHO has done a great public service by stepping up and publicly declaring what many of us in the field have long known — this is a serious risk.

WHO core principles "require that everyone associated with financing and supporting health-care activities should provide for the costs of managing health-care waste. This is the duty of care. Manufactures also share a responsibility to take waste management into account in the development and sale of their products and services."

The WHO goes on to identify those who have a special responsibility to ensure safe collection, containment and disposal of these wastes, placing much of that responsibility with the chief pharmacist. "The chief pharmacist also has the special responsibility of ensuring that genotoxic products are used safely, and that genotoxic waste is managed safely," according to the WHO.

Jim Mullowney is the founder and CEO of Newport-based Pharma-Cycle Inc

Media Contact: Jim Mullowney, Pharma-Cycle, Inc., 617-755-0883, jmullowney@pharma-cycle.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Pharma-Cycle, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Big Pharma to Come Together at ChemOutsourcing 2013 in Long Branch, New Jersey, Sept 16-19
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. ChemOutsourcing Announces 100 CMO and CRO Exhibitors for September 2013 Show in Long Branch, New Jersey
4. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
7. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
8. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
9. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
10. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 23, 2017  HealthMine surveys with 9,250 insured consumers ... health plan members want help from their plans in ... in their health, 2) help closing gaps in care, ... health and 5) relevant, real-time guidance. Meeting these needs ... costs. A Reason to Stay ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... Definitive Financing Commitment Term Sheet (the "Definitive Financing") ... group of the Company,s stockholders, who are referred ... in a Form 8-K filed with the Securities ...
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... According to a new study by NCPA Senior Fellow John R. ... rules Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare ... it estimates a reduction in employer-based coverage due to the GOP reform, which is ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... March 24, 2017 , ... As ... to create a communications platform that positions them as the go-to thought leader ... reinvented their online publication as an always-on, always-fresh news, views and advocacy engine, ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June ... ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present on: ... of cases litigated under ERISA involve claims for long-term disability benefits. This ...
Breaking Medicine News(10 mins):